Sarepta issued press release on June 15, 2025, titled “Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne.” As it examines the data, the company has initiated several safety initiatives.
Read morePersonalized Gene Therapy
A research team from CHOP and the Perelman School of Medicine at the University of Pennsylvania, supported by the National Institutes of Health, developed a customized gene therapy by utilizing the gene editing platform CRISPR.
Read morectDNA testing and treatment of stage 3 colon cancer
Clinical trial for stage 3 colon cancer shows promise.
Read moreNo Pain, No...Addiction?
On January 30, 2025, the United States FDA approved medication Journavx (suzetrigine), a first-in-class, non-opioid analgesic to treat moderate to severe acute pain in adults.
Read moreGene Therapy Summary 2019-2024 from a Reinsurance/Stop Loss Perspective
Summit Re sees increasing number of gene therapy cases.
Read moreMedicare Drug Price Negotiation
CMS initially selected ten drugs covered under Part D for the first cycle of negotiations with drug companies. These drugs include Januvia, NovoLog, Farigia, Enbrel, Jardiance, Stelara, Xarelto, Eilquis, Entresto, and Imbruvica.
Read moreBrian Fehlhaber Retires from Summit Re
Senior Vice President Brian Fehlhaber has retired from Summit Re, effective January 3, 2025.
As you may know, Brian was one of the original founders of Summit Re in 1999, and he continued to shepherd the company’s reinsurance sales efforts through his last day. His contributions not only have helped Summit Re grow and thrive over the last 25 years, but he has also assisted so many clients and industry colleagues with their own strategic direction, both professionally and personally. Brian’s passion for the industry has been second to none, and his selfless and consultative approach has allowed Summit Re to differentiate itself in the industry. Brian has traveled more miles on Summit Re’s behalf than anyone else—perhaps even collectively—and we are exceedingly grateful for all he has done to promote our company and this industry.
Brian has left Summit with a very strong and capable sales team. Over the past few years, Brian has transitioned his direct responsibility for individual accounts so that he could focus his activities on strategic oversight. To that end, day-to-day client responsibilities are already well looked after. We appreciate the thoughtful care with which Brian has readied this company for his retirement.
We wish Brian the very best in this next phase!
Gene and Cell Therapy Update
November ushered in two new therapies, AUCATZYL® (obecabtagene autoleucel), a CAR-T therapy which was approved on 11/8/2024, and Kebilidi™ (eladocagene exuparvovec-tneq), a gene therapy which was approved on 11/13/2024.
Read moreNew Treatment for Uveal Melanoma: HEPZATO
Uveal melanoma is the most common primary intraocular malignancy, and while several local therapies can be offered for primary disease control such as plaque brachytherapy, proton therapy and enucleation, effective therapies to control distant disease have been limited.
Read morePfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) from Worldwide Markets
Pfizer announced on September 25, 2024, that they are voluntarily withdrawing all lots of OXBRYTA (voxelotor) and discontinuing all active clinical trials and expanded access programs worldwide.
Read more